Evidence map›Paper›PMID 41878954›Full record

Observational studyCancer medicine2026

Long-Term Survival Outcomes of Concurrent Chemoradiotherapy for Postoperative High-Risk Salivary Gland Carcinomas.

Shengjin Dou, Xin Wang, Lin Zhang, Wen Jiang, Lulu Ye, Yu Wang, Rongrong Li, Guopei Zhu

Registry-linked trialAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02776163 (Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas of Head and Neck, A Non-Randomized, Phase II Trial), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02776163 phase2completednot on this map

Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas of Head and Neck, A Non-Randomized, Phase II Trial

TypeinterventionalSponsorShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityRan2016 to 2023Enrolled107ConditionsSalivary Gland Tumors, Head and Neck CancerArmsNedaplatin, Docetaxel, Intensity-modulated radiotherapy
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shengjin DouDepartment of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0002-6530-641X
Xin WangDepartment of Radiation Oncology, Shanghai Second People's Hospital, Shanghai, China.
Lin ZhangDepartment of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Wen JiangDepartment of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lulu YeDepartment of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yu WangDepartment of Oral Pathology, Shanghai Ninth People's Hospital Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
Rongrong LiDepartment of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-3621-2366
Guopei ZhuDepartment of Oral and Maxillofacial-Head Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.ORCID https://orcid.org/0000-0003-4770-9458

Funding

Shanghai Municipal Health Commission 201640158
6 · The paper itself

Abstract

backgroundThis study evaluated the long-term survival outcomes of concurrent chemoradiation (CCRT) for high-risk salivary gland carcinomas (SGCs).

methodPostoperative patients with high-risk SGCs, other than adenoid cystic carcinoma (ACC), with T3-4/N1-3M0 disease were enrolled. This study included a cohort of 55 patients who received CCRT, derived from a prospective phase II trial, and a retrospective cohort of 61 patients treated with RT alone.

resultsThe median follow-up for survivors was 54.1 months. In the subgroup analysis, patients without ENE treated with CCRT showed significantly better 5-year OS (83.4% vs. 69.0%, p = 0.032), with a numerically higher 5-year DFS (57.3% vs. 41.6%, p = 0.062). In the subgroup of patients with N0-1 disease, those treated with CCRT showed a numerically higher 5-year DFS (69.1% vs. 44.9%, p = 0.073) and OS (90.7% vs. 76.2%, p = 0.057). On multivariate analyses, CCRT significantly predicted superior DFS (p = 0.021) and OS (p = 0.004) for patients without ENE and superior DFS (p = 0.027) for patients with N0-1 disease.

conclusionFor postoperative high-risk non-ACC SGCs, CCRT was associated with improved long-term survival outcomes in patients without ENE or with N0-1 disease, which need further evaluation in randomized trials. However, for patients with ENE or N2-3 disease, they may need alternative treatment strategies to enhance their prognosis.

trial registrationThe prospective cohort analyzed in this study originated from the non-ACC group enrolled in a phase 2 clinical trial (NCT02776163).

Indexed as

ChemoradiotherapySalivary Gland NeoplasmsAdultAgedClinical Trials, Phase II as TopicFemaleHumansMaleMiddle AgedNeoplasm StagingRetrospective StudiesTreatment Outcomechemotherapyhigh‐riskpostoperativeradiotherapysalivary gland carcinoma

Identifiers

PMID41878954
PMCPMC13140899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.